Get the Stockscreener App
5.315
0.38%
0.045
Perspective Therapeutics Inc stock is traded at $5.315, with a volume of 113.43K.
It is up +0.38% in the last 24 hours and up +14.25% over the past month.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$5.27
Open:
$5.22
24h Volume:
113.43K
Relative Volume:
0.04
Market Cap:
$604.88M
Revenue:
$6.96M
Net Income/Loss:
$-46.51M
P/E Ratio:
-30.97
EPS:
-0.1716
Net Cash Flow:
$-37.99M
1W Performance:
+4.55%
1M Performance:
+14.25%
6M Performance:
+52.89%
1Y Performance:
+109.09%
1-Day Range:
$5.16
$5.34
1-Week Range:
$4.91
$5.495
52-Week Range:
$1.60
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
5.31 | 600.33M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
111.66 | 196.53B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
375.79 | 146.14B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
93.69 | 122.74B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
71.64 | 107.15B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
84.63 | 49.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | Piper Sandler | Overweight |
| Nov-24-25 | Resumed | Truist | Buy |
| Oct-10-25 | Initiated | BTIG Research | Buy |
| Mar-13-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-01-24 | Initiated | Wedbush | Outperform |
| Sep-25-24 | Initiated | Truist | Buy |
| Jul-25-24 | Initiated | BofA Securities | Buy |
| May-09-24 | Initiated | Cantor Fitzgerald | Overweight |
View All
Perspective Therapeutics Inc Stock (CATX) Latest News
Perspective Therapeutics (CATX) director awarded 50,000-share stock option grant - Stock Titan
Director at Perspective Therapeutics (CATX) awarded 50,000 stock options - Stock Titan
Director at Perspective Therapeutics (CATX) awarded 50K stock options - Stock Titan
Perspective Therapeutics (CATX) CAO receives 90,000-stock-option equity award - Stock Titan
Perspective Therapeutics (CATX) CMO receives 150,000 stock options as 2026 award - Stock Titan
CATX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
CATX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CATX SEC FilingsPerspective Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Does Perspective Therapeutics Inc stock have upside surprise potential - baoquankhu1.vn
Market Review: What is the next catalyst for Perspective Therapeutics IncGDP Growth & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Take Profit: Does Perspective Therapeutics Inc stock have upside surprise potentialShort Setup & Stock Portfolio Risk Management - baoquankhu1.vn
Perspective Therapeutics (NASDAQ:CATX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Perspective Therapeutics (CATX) and Its Rivals Head to Head Survey - Defense World
349,323 Shares in Perspective Therapeutics, Inc. $CATX Purchased by Patient Square Capital LP - MarketBeat
CATXPerspective Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Perspective Therapeutics (NASDAQ:CATX) Coverage Initiated at Piper Sandler - Defense World
Radioligand Therapies Market Size, Share | Growth Report 2034 - Fortune Business Insights
Perspective Therapeutics (NASDAQ:CATX) Rating Increased to Strong-Buy at Piper Sandler - MarketBeat
Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price Up 12.3%Still a Buy? - MarketBeat
Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price Up 12.3% – Still a Buy? - Defense World
Piper Sandler initiates Perspective Therapeutics stock rating at overweight By Investing.com - Investing.com Nigeria
Perspective Therapeutics (CATX) Receives a Buy from JonesTrading - The Globe and Mail
This Tempus AI Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
CATX Initiates Coverage with Overweight Rating by Piper Sandler - GuruFocus
Piper Sandler Initiates Coverage of Perspective Therapeutics (CATX) with Overweight Recommendation - Nasdaq
Piper Sandler initiates Perspective Therapeutics stock rating at overweight - Investing.com UK
Piper Sandler Initiates Coverage on Perspective Therapeutics With Overweight Rating - marketscreener.com
Perspective Therapeutics, Inc. (CATX) Builds Momentum With Funding and Trial Progress - Insider Monkey
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else - Benzinga
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results - Bitget
Contrasting Perspective Therapeutics (CATX) and Its Peers - Defense World
Financial Review: Perspective Therapeutics (CATX) & Its Rivals - Defense World
How Perspective Therapeutics Inc. stock reacts to new regulations2025 Pullback Review & Long-Term Growth Portfolio Plans - mfd.ru
CATX Technical Analysis & Stock Price Forecast - Intellectia AI
CATX PE Ratio & Valuation, Is CATX Overvalued - Intellectia AI
Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW), Icon (ICLR) and Perspective Therapeutics (CATX) - The Globe and Mail
Can Perspective Therapeutics Inc. lead its sector in growthDividend Hike & Low Drawdown Investment Ideas - mfd.ru
Will Perspective Therapeutics Inc. benefit from rising consumer demandJuly 2025 Patterns & Low Risk High Win Rate Stock Picks - mfd.ru
Perspective Therapeutics Outperforms Competitors in Key Metrics - National Today
Can Perspective Therapeutics Inc. expand into new marketsLayoff News & Safe Capital Investment Plans - mfd.ru
Activity Recap: Does Perspective Therapeutics Inc stock have upside surprise potentialExit Point & Technical Buy Zone Confirmations - baoquankhu1.vn
Perspective Therapeutics (CATX) Is Up 92.6% After $175M Equity Raise To Fund Targeted Alpha Therapies – Has The Bull Case Changed? - Yahoo Finance
Perspective Therapeutics Raises Capital to Advance Radiopharmaceutical Pipeline - TipRanks
Perspective Therapeutics Prices Approx. $175 Mln Offering Of Shares And Pre-Funded Warrants - Nasdaq
Perspective Therapeutics (CATX) Raises $175 Million Through Stoc - GuruFocus
Perspective Therapeutics shares rise after $175 million offering By Investing.com - Investing.com South Africa
Perspective Therapeutics shares rise after $175 million offering - Investing.com
Perspective Therapeutics jumps after $175 mln equity offering - TradingView
Perspective Therapeutics (CATX) Announces $175M Public Offering - GuruFocus
Perspective Therapeutics prices 39.58M shares at $3.79 in underwritten offering - TipRanks
Perspective Therapeutics prices $175M equity offering; shares up - MSN
Perspective Therapeutics Inc Stock (CATX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.60%
Cap:
|
Volume (24h):